Xiang'an Hospital (XAH), funded by Xiamen Council and Xiamen University, is a non-profit, public hospital with proposed Triple-A Grade which is the highest level in Chinese hospital standards, where medical prevention, treatment, education and scientific research are undertaken. Being a research-based hospital affiliated to Xiamen University, XAH follows the University’s motto “Pursue Excellence; Strive for Perfection”, our strategic vision is to be one of the top hospitals in China and recognized internationally.

Currently XAH has completed first stage of construction, funded CNY 2 billion on a 12Ha ground, with floor area 152 thousand square meters and 1,000 beds. We now offer a range of service facilities including Outpatient Building, Emergency and Critical Building, Medical Technology Building, Science & Education Building, and 2 Inpatient Buildings, equipped with the most advanced medical diagnosis and treatment devices such as 3.0T MRI, Dual Source CT, and VitalBeam Medical Linear Accelerator etc. With ongoing investment and development, our next stage of construction will expand to 24Ha ground and 3,000 beds.

Combined with Xiamen University’s strong resources in Oncology, Diagnosis Medicine, Ophthalmology, and Chinese Medicine etc, XAH focuses on establishment of a high-level medical system. Cancer Centre, Organ Transplant Centre, Medical diagnosis Centre, Emergency and Critical Centre, Geriatric Disorders Centre, and Neurological Disorders Centre are on the way. Meanwhile we have a strong staff team covering most of medical specialties, including CAS and CAE Members, Professors of Changjiang Scholar's Program, Head of PLA Specialist Center, Provincial Medical Principle, Discipline leaders, etc.

Supported and funded by governmental programs for over CNY 16 million, Prof Zhang is dedicated in the studies of breast cancer’s development mechanism and precise therapy.

●   Discovery of role of Notch3 signal pathway in breast cancer.  Notch3 inhibits epithelial mesenchymal transition (EMT) by regulating many factors, such as ERα, Hippo / YAP and GATA3. Notch3 is also regulated by upstream factors such as Id2 and miR-221 / 222. This is the first time to confirm the role as tumor suppressor of Notch3 in breast cancer, especially in luminal breast cancer. This is also the unique role of Notch3 in breast cancer, which is different from in other malignant tumors. These results initially solved the controversy about the function of Notch3.

●   Establishment of visual report systems of cell cycle and EMT process. The S phase reporter Cyclin A2-Luc was established by using fusion protein technology to monitor the therapeutic effects of S phase-targeted drugs, such as 10-Hydroxycamptothecin in vitro and in small animals. Meanwhile, a reporter was constructed to monitor the expression level of miR-200c, a molecular marker of EMT, which can track the genesis, development, invasion and metastasis of tumor, and provide an effective platform for screening drugs for inhibiting tumor invasion and metastasis.

●   Development and application of optical molecular imaging on surgical navigation in breast cancer. His team was the first in China to propose the concept of “Optical Imaging Toolbox”, which means a great significance of optical imaging diagnosis and treatment of malignancies. His team developed a near-infrared fluorescent imaging technology and adaptable device that are capable and efficient for small tumors detection and tumor margin delineation.

Through many years of innovative works, he has presented 2 China patents, and over 140 papers in peer-reviewed journals like Nature Medicine, Nature Protocols, PNAS and Cancer Letters. He also serves as International Associate Editor of “Molecular Imaging and Biology”, Editor of “International Journal of Biochemistry and Cell Biology”, and Associate Editor of “American Journal of Nuclear Medicine and Molecular Imaging”.

We value postdoc research as an important step on the academic career path, offering the opportunity to work on a key project alongside experts in one of our academic fields such as Oncology, Translational Medicine, Molecular Imaging, Surgery, Internal Medicine, Biochemistry, Molecular Biology, Bioinformatics, Genetics, etc.

Please read carefully below the minimal criteria.

1. Qualifications

1) Healthy mental and physical conditions.

2) 35 years old or younger.

3) Less than 3 years after PhD obtained in renowned universities/academic organizations.

4) Published papers, either 2 in JCR Q3 or 1 in Q2.

2. Working responsibilities

1) Independently conduct research program under team work, minimal outcomes required.

2) Reasonable jobs as appointed from time to time.

3. Salary, allowance and bonus

Totally CNY160,000 or over depending on assessment and outcomes.

4. Contact

Please send your CV, at least including personal info, education, academic and working experiences, and research plan, with 2 or more refs, to rmzhang@xah.xmu.edu.cn.

Thank you for your interests in this position.